SV2017005405A - Compuestos y composiciones como inhibidores de quinasa raf - Google Patents

Compuestos y composiciones como inhibidores de quinasa raf

Info

Publication number
SV2017005405A
SV2017005405A SV2017005405A SV2017005405A SV2017005405A SV 2017005405 A SV2017005405 A SV 2017005405A SV 2017005405 A SV2017005405 A SV 2017005405A SV 2017005405 A SV2017005405 A SV 2017005405A SV 2017005405 A SV2017005405 A SV 2017005405A
Authority
SV
El Salvador
Prior art keywords
compounds
compositions
quinasa
raf inhibitors
therapeutic
Prior art date
Application number
SV2017005405A
Other languages
English (en)
Inventor
Matthew T Burger
Savithri Ramurthy
Benjamin R Taft
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2017005405A publication Critical patent/SV2017005405A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA I: (VER FORMULA); DONDE X, Y, Z, R1 Y R2 SON COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO, Y SALES DE LOS MISMOS Y USOS TERAPÉUTICOS DE ESTOS COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LA ACTIVIDAD DE LA QUINASA RAF. LA INVENCIÓN PROPORCIONA ADEMÁS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, Y COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS Y UN CO-AGENTE TERAPÉUTICO
SV2017005405A 2014-09-12 2017-03-10 Compuestos y composiciones como inhibidores de quinasa raf SV2017005405A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049469P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
SV2017005405A true SV2017005405A (es) 2018-04-04

Family

ID=54148595

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005405A SV2017005405A (es) 2014-09-12 2017-03-10 Compuestos y composiciones como inhibidores de quinasa raf

Country Status (30)

Country Link
US (2) US9573969B2 (es)
EP (1) EP3191472B1 (es)
JP (1) JP6678655B2 (es)
KR (1) KR20170053686A (es)
CN (1) CN107108671B (es)
AP (1) AP2017009830A0 (es)
AR (1) AR101815A1 (es)
AU (1) AU2015313782B2 (es)
BR (1) BR112017004741A2 (es)
CA (1) CA2960971A1 (es)
CL (1) CL2017000541A1 (es)
CO (1) CO2017002292A2 (es)
CR (1) CR20170092A (es)
CU (1) CU20170026A7 (es)
DO (1) DOP2017000066A (es)
EA (1) EA031061B1 (es)
EC (1) ECSP17021897A (es)
ES (1) ES2729243T3 (es)
IL (1) IL250950A0 (es)
MX (1) MX2017003233A (es)
NI (1) NI201700029A (es)
PE (1) PE20171338A1 (es)
PH (1) PH12017500416A1 (es)
SG (1) SG11201701734QA (es)
SV (1) SV2017005405A (es)
TN (1) TN2017000075A1 (es)
TW (1) TWI603977B (es)
UY (1) UY36294A (es)
WO (1) WO2016038581A1 (es)
ZA (1) ZA201701633B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TN2016000270A1 (en) * 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN108047240B (zh) 2014-09-12 2020-08-04 勃林格殷格翰国际有限公司 组织蛋白酶c的螺环化合物抑制剂
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
SG11201913249SA (en) * 2017-08-03 2020-02-27 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
CA3133812A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
JP2022532034A (ja) 2019-05-03 2022-07-13 キネート バイオファーマ インク． Ｒａｆキナーゼの阻害剤
WO2021081375A1 (en) * 2019-10-24 2021-04-29 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022066580A1 (en) * 2020-09-23 2022-03-31 Kinnate Biopharma Inc. Raf degrading compounds
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
CN117529313A (zh) * 2021-04-23 2024-02-06 金耐特生物制药公司 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐
KR20240000534A (ko) 2021-04-23 2024-01-02 킨네이트 바이오파마 인크. Raf 억제제를 이용하는 암의 치료
KR20240007205A (ko) * 2021-05-12 2024-01-16 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 N-연결된 사이클릭 치환체를 갖는 피리딘 유도체

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0923579A1 (en) 1996-08-27 1999-06-23 Novartis AG Herbicidal s-substituted 1,2,4,6-thiatriazines
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2000061576A1 (en) 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
US6310574B1 (en) 1999-08-05 2001-10-30 Vega Grieshaber Kg Level transmitter
JP2003509501A (ja) 1999-09-23 2003-03-11 アストラゼネカ・アクチエボラーグ 治療薬キナゾリン化合物
MXPA02005106A (es) 1999-11-22 2002-11-07 Smithkline Beecham Plc Compuestos novedosos.
EP1251849A1 (en) 2000-01-18 2002-10-30 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CN1230166C (zh) 2000-01-18 2005-12-07 沃泰克斯药物股份有限公司 回旋酶抑制剂及其用途
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
HU1300187D0 (hu) 2000-06-12 2004-03-01 Eisai R&D Man Co Ltd 1,2-Dihidropiridin-származékok, eljárás elõállításukra és alkalmazásuk
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
DE60129154T2 (de) 2000-11-20 2008-02-28 Smithkline Beecham Corp. Neuartige verbindungen
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US7279477B2 (en) 2001-01-26 2007-10-09 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
WO2002062792A1 (fr) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP4518956B2 (ja) 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク トランスフォーミング成長因子（ｔｇｆ）阻害剤としての新規トリアゾールおよびオキサゾール化合物
EA200500378A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1673343A4 (en) 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
JP4755991B2 (ja) 2003-10-16 2011-08-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
EP1721905A4 (en) 2004-03-05 2009-11-18 Taisho Pharmaceutical Co Ltd THIAZOLE DERIVATIVE
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
CA2682189C (en) 2006-04-07 2015-12-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
SG182958A1 (en) 2007-06-27 2012-08-30 Astrazeneca Ab Pyrazinone derivatives and their use in the treatment of lung diseases
EP2167497A2 (en) 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
JP2010533159A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RU2474580C2 (ru) 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
TW200916458A (en) 2007-09-05 2009-04-16 Astrazeneca Ab Heterocyclic compounds and methods of use thereof
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
MX2011000738A (es) 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP3354650B1 (en) 2008-12-19 2022-02-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2009334997A1 (en) * 2008-12-30 2011-08-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as Raf kinase inhibitors
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP2470532A1 (en) * 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase
WO2011026911A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
WO2011059610A1 (en) 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
US8796320B2 (en) 2009-12-28 2014-08-05 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-Oxadiazole-2-carboxamide compound
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
CN103080107A (zh) 2010-06-25 2013-05-01 诺瓦提斯公司 作为蛋白激酶抑制剂的杂芳基化合物和组合物
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
MX339937B (es) 2011-09-01 2016-06-17 Novartis Ag * Compuestos y composiciones como inhibidores de la quinasa c-kit.
CN102993199A (zh) * 2011-09-09 2013-03-27 山东轩竹医药科技有限公司 杂环取代的吡啶并吡咯激酶抑制剂
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
US9399638B2 (en) 2012-05-02 2016-07-26 Lupin Limited Substituted pyridine compounds as CRAC modulators
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
TW201414704A (zh) 2012-07-02 2014-04-16 Biogen Idec Inc 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Also Published As

Publication number Publication date
ES2729243T3 (es) 2019-10-31
CO2017002292A2 (es) 2017-06-20
CU20170026A7 (es) 2017-07-04
WO2016038581A1 (en) 2016-03-17
EA031061B1 (ru) 2018-11-30
MX2017003233A (es) 2017-05-23
NI201700029A (es) 2017-04-04
TN2017000075A1 (en) 2018-07-04
ZA201701633B (en) 2018-05-30
DOP2017000066A (es) 2017-04-16
EP3191472B1 (en) 2019-03-06
CN107108671B (zh) 2019-10-01
AR101815A1 (es) 2017-01-11
EP3191472A1 (en) 2017-07-19
ECSP17021897A (es) 2018-02-28
US20170114083A1 (en) 2017-04-27
AU2015313782B2 (en) 2018-09-13
KR20170053686A (ko) 2017-05-16
SG11201701734QA (en) 2017-04-27
US9809610B2 (en) 2017-11-07
JP6678655B2 (ja) 2020-04-08
JP2017528475A (ja) 2017-09-28
US20160075727A1 (en) 2016-03-17
AP2017009830A0 (en) 2017-03-31
BR112017004741A2 (pt) 2017-12-05
TW201613945A (en) 2016-04-16
US9573969B2 (en) 2017-02-21
CA2960971A1 (en) 2016-03-17
TWI603977B (zh) 2017-11-01
EA201790599A1 (ru) 2017-06-30
UY36294A (es) 2016-04-29
PE20171338A1 (es) 2017-09-13
AU2015313782A1 (en) 2017-03-30
CN107108671A (zh) 2017-08-29
PH12017500416A1 (en) 2017-07-17
IL250950A0 (en) 2017-04-30
CL2017000541A1 (es) 2017-08-18
CR20170092A (es) 2017-05-08

Similar Documents

Publication Publication Date Title
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2016000173A (es) Heteroarilos y usos de estos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
BR112016023558A2 (pt) compostos úteis como imunomoduladores
NI201600071A (es) Compuestos de inhibidor de autotaxina
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY35991A (es) Bencimidazol-2-aminas como inhibidores de midh1
UY35823A (es) Profármacos de antagonista de nmda
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY36464A (es) Compuestos de quinazolina
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo